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Abstract
Background: Circulating Tumor Cells (CTCs) are promising biomarkers for monitoring solid cancer and were used
to monitor brain tumors. Here we report two cases in which, for the first time, CTCs were used in cytological
diagnostic evaluation to discriminate a space-occupying lesion of the brain.
Case presentation: Two cases of focal intracranial lesions, unclassified for diagnosis, untreated and apparently
symptomatic, were examined after high-contrast resolution Magnetic Resonance Imaging and/or Computed
Tomography scans. CTCs were seeded on chamber slides and short-time expanded under the optimized conditions
as we previously reported. The first case was a focal lesion localized in the parietal-occipital area in a 67-year-old
woman. The second case was a 31-year-old man with an expansive intracerebral lesion localized in the left peri-trigonal
area. Both patients underwent excisional biopsy. Histopathological evaluation of the biopsy confirmed the previous
cytological diagnoses, and the analysis of the clinical outcomes retrospectively validated both diagnoses.
Conclusions: The cases here reported illustrate the potential for using expanded CTCs as non-invasive, real-time
biopsy. Moreover, non-invasive real-time biopsy can represent an alternative diagnostic tool to be used when a
functional area of the brain is at risk of injury from excisional biopsy procedures.
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Background
The use of new technologies to detect Circulating
Tumor Cells (CTCs) in the bloodstream of cancer
patients has resulted in a better understanding of the
biology of solid cancer and related circulating progeny
[1]. It now appears clear that the primary tumor gener-
ates circulating progeny not only during the phase of
disseminated malignancy [2]. Many studies have shown
that this phenomenon occurs in each phase of cancer
development [3]. Isolated tumor cells have been detected
in the bone marrow of up to 16 % of the American Joint
Committee on Cancer stage I and II of breast cancer
[4, 5]. CTCs come from the initial phase of a tumor
and from eventual metastasis. CTCs are able to go back to
the primary tumor site and therefore participate in the
formation of relapsing lesions [6]. Up to now, different
hypotheses have tried to explain their presence in the per-
ipheral blood of patients affected by intracranial malignan-
cies [7]. In fact, the intracerebral localization implicates
the interaction of the tumor bulk and its cancer cell pro-
geny with the Blood Brain Barrier (BBB). The BBB con-
sists in an endothelial wall, where cells are connected by
tight junctions, surrounded by astrocytic end-feet with
pericytes embedded in the vessel basal membrane. More-
over, neurons and microglia are involved in the cytoarchi-
tecture of BBB. Therefore, the first condition for the
cancer cell progeny to intravasate seems to be closely
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associated with altered BBB permeability. In theory, focal
disturbances in the BBB could happen in every stage of
intracranial malignancies development, due to inflam-
matory conditions or direct interaction with tumor cells
[8, 9]. Study on glioblastoma cancer showed that glioma
cells displace, or even eliminate, astrocytic end-feet and
directly enter in contact with endothelial cells. These in-
teractions result in a breach of BBB that justify the CTCs
detection. CTCs have been described only in cases of ad-
vanced glioblastoma [10] and, in literature, the actual
delay between the initial tumor diagnosis and metastasis
ranges between 1 and 60 months [11].
In intracranial pathologies, a further limit in the use of
CTCs as biomarkers is set by the prevalent detection of
CD326 expression through the most used technique,
Cell Search. Indeed, tumor cells in endocranial tumors
lose or do not express CD326 [12]. As a result, research
has been carried out by analyzing peripheral blood in
patients affected by endocranial tumors and seeking cir-
culating markers such as tumoral DNA or regulatory
mRNA or oncoproteins [13]. Recent research has shown
that CTCs isolated from patients with glioblastoma are
enriched with mesenchymal markers [14].
We have previously described an optimized protocol
to isolate and short-time expand CTCs derived from
cancer patients [1, 15].
The protocol involves the isolation of CTCs from per-
ipheral blood as shown in Fig. 1(a-f ). As described in
previous papers, we have identified a specific density
phase for CTCs in peripheral blood [15, 16]. In intracra-
nial cases reported here, we verified that the previous
identified phase was enriched with CTCs (Fig. 1a-d).
The cells isolated from this phase are then put to seed-
ing, as previously described [1, 15, 16], in a specific cul-
ture medium and expanded for 14 days (Fig. 1e). The
short-time cultivation protocol has been optimized in
the course of many experiments which have allowed us
to pinpoint the time required to show up the prolifera-
tive capacity of the transformed cells and to preserve
their original phenotypes. Our approach does not make
any selection of phenotypes during the initial phase, in
order to save the heterogeneous composition of the
CTCs. In fact, the circulating tumor progeny we expect
to be made up of cancer cells with an epithelial or mes-
enchymal or hybrid epithelial-mesenchymal phenotypes.
Our purpose here is only to highlight the proliferation
capability, which is typical of a transformed cell when
compared to a normal cell. The chamber-slides are not
pre-treated in order to promote the cells with high sur-
vival and proliferative capacities. The slides with cells in
adhesion are useful for pathological analysis. Further-
more, the cells, which have grown in adhesion and
Fig. 1 CTCs isolation procedure. CTCs isolation was performed on a whole blood sample previously treated with a solution for lysing red blood
cells (a), and on a specific phase (after gradient procedure performed centrifuging the peripheral blood mounted on Ficoll) (c). Peripheral blood
sample is achieved by searching for cells expressing Vimentin. The reported dot plots in b) (obtained from the analysis of whole blood sample) vs d)
(obtained from the analysis after gradient procedure) confirm that the specific phase is enriched for CTCs. Finally, the CTCs were seeded on slide
chamber and expanded for 14 days (e). Cultivated CTCs were stained for immunofluorescence analysis (f) highlighting the nuclei in blue, DAPI stained
(a), and in red Vimentin expression (b). Scale bar: 200 μm
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suspension, can be classified according to the mesenchy-
mal antigen vimentin expression (Fig. 1f ).
Here, we report two cases of intracranial tumor whose
sizes range between 0,5–4 cm, and in these cases we
have isolated CTCs and recovered them on chamber-
slides for a short-time culture. CTC-slides were then used
for cytological evaluation [17]. These cases represent the
first example of how CTCs can be used as biomarkers in
the diagnostic phase of tumors such as the endocranial
ones, for which the current imaging techniques do not




In November 2013 a 67-year-old female with negative
familiar history for any type of tumor lamented asthenia,
mental confusion, memory disturbances, dizziness, de-
creased vision and partial right homonymous hemianop-
sia. These symptoms gradually worsened over a period
of a few days. The patient was referred to us for observa-
tion accusing the above symptoms and she underwent a
complete neurological investigation. The results of the
investigation excluded a deficiency in the cranial nerves
and an Magnetic Resonance Imaging (MRI) scan was re-
quested. A pre-operative MRI was performed which
highlighted an expansive lesion altering the signals at
the left temporal lobe and the left posterior occipital
lobe (Fig. 2a). The presence of oedema determined com-
pression of the occipital horn of the lateral ventricle.
Moreover, extensive alteration of the signal from the left
temporal, occipital and posterior parietal lobes, with
swollen appearance of the parenchyma and resulting
compression on the occipital horn were reported. The
lesion was mainly located in the left occipital region
showing a circular, ring-like distribution of the contrast.
A ring contrast-enhanced lesion localized in the left
occipital region with intralesional hypointensity are not
pathognomonic for glioblastoma. At the same time the
site, the compression on the ventricle, the oedema and the
persistent symptoms made the patient a candidate for sur-
gical intervention to remove the lesion tissues. The initial
patient’s performance status according to the Eastern
Cooperative Oncology Group (ECOG) was classified as
ECOG= 1. During the pre-operative phase, as well as the
routine blood tests, a sample of peripheral blood in EDTA
was taken for analysis of the CTCs. Peripheral blood sam-
ple is collected to detect CTCs. We used whole peripheral
blood pre-treated with a red cells lysis solution (Fig. 1a)
and in parallel we performed gradient procedure (Fig. 1c)
as previously reported [15]. The reported dot plots in
Fig. 1b) vs d), confirm that the gradient phase is enriched
in CTCs Vimentin positive (Vimentinpos) as previously
demonstrated for other type of tumors [1, 15, 16].
After 14 days of CTCs expansion, the chambers were
eliminated and the adherent cancer cells were fixed with
Cytofix aerosol preparation for pathological analysis.
The pathologist diagnosed an high grade astrocytic
tumor due to neoplastic cells with gemistocytic pattern
and nuclear atypia, in Haematoxylin and Eosin (H&E)
stained slide (Fig. 2c).
In December 2013 the patient underwent a bulk resec-
tion of the lesion: a left parietal-occipital craniotomy
was performed and no complications were found after
surgery. Post-surgery recovery was satisfying, the man-
agement of the patient during the post-surgical phase
did not present significant problems; antioedema and
antibiotic therapies were administered and the patient
recovery time was 10 days. The patient was dismissed
10 days after surgery. The clinical symptoms disappeared
except for the persistent right homonymous hemianopsia.
The cancer tissue excised during surgery was analysed by
a pathologist (Fig. 2d).
The pathologist diagnosed a multiform glioblastoma
due to neoplastic tissue with severe atypical astrocyte
proliferation in presence of mitosis and microvascular
proliferation. This diagnosis was confirmed using immu-
nohistochemistry techniques.
The specialists advised adjuvant “whole brain” radio-
therapy. Total radiotherapy dose was 60 Gy delivered in
30 consecutive days associated with temozolomide.
The patient tolerated the antitumor therapy well with-
out showing modification of the initial performance.
In January 2014 a second peripheral blood sampling
for CTCs isolation was performed. The cytological ana-
lysis of the resulting slide highlighted the persistence of
CTCs in the peripheral blood, with an increased concen-
tration of 7 CTCs-Vimentinpos/ml, compared to the first
blood sampling (4,5 CTCs-Vimentinpos/ml).
After 9 month of apparent wellness and clinical bene-
fit, in October 2014 the patient returned to us complain-
ing difficulty in maintaining a standing position, urinary
incontinence and further reduction in vision that led to
complete hemianopsia. A brain MRI revealed a recur-
rence of the tumor which showed as an irregular area
with increased absorption of the contrast. In particular,
T2-hyperintense and T1-hypointense highlighted perifo-
cal oedema in left parietal-temporal-occipital area. The
ipsilateral occipital horn appeared partially dislocated,
while the hippocampal cortex, the hippocampus and the
midbrain appeared dislocated to the left, with a slight
shift of the midline (Fig. 2b). The patient was treated
with anti-oedema agents, mannitol and cortisone to re-
duce the symptoms. Only in February 2015 the patient
agreed to undergo surgery to excise the relapsing lesion.
The surgeons carried out a second surgical resection of
the left parietal-occipital lesion. Conditions of the pa-
tient in the post-surgical phase were complicated by the
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formation of a fistula containing liquid on the operation
site. Anti-oedema and antibiotic therapies were adminis-
tered. The histopathologic examination was diagnostic
for a recurrence of a glioblastoma. The patient’s general
state of health began to worsen and she died in March
2015.
Case 2
In May 2015 a 31-year-old man presented with a one-
month history of headaches associated with phonophobia
and photophobia, dizziness and short term memory
deficits. On admission, he was somnolent and disoriented.
He had bilateral papilledema and left homonymous
hemianopsia.
Laboratory examinations showed 14500/mm3 white
blood cell count, 558 UI/Lactate dehydrogenase (LDH).
Cerebrospinal fluid analysis showed high values in pro-
teins and glucose whereas the cytology was negative.
Computed Tomography (CT) scans showed a cystic ex-
pansion entrapping the temporal horn of the left lateral
Fig. 2 Clinical cases. Case 1 (sequence a-d) is shown in red and case 2 is shown in blue (sequence e-h). The MRIs were carried out during the
clinical course of preliminary diagnosis (a and e) with liquid biopsy (c and g). Diagnosis was subsequently confirmed by conventional tissue
biopsy (d and h). Finally, MRIs as part of the follow-up were respectively reported for the two cases (b and f). Case 1. In a pre-operative MRI of
the head shows an expansive lesion with peritrigonal localization. The lesion dislocates the ventricular system with relative dilatation of the left
temporal horn. The parenchymal side of the lesion, after contrast infusion, shows a strong enhancement in respect to the perilesional oedema.
Para-sagittal and coronal sections after contrast perfusion show the lesion proximal to the IV cerebral ventricle. In b MRI, performed during the
follow up, shows relapsing lesion. In c Liquid biopsy, H&E staining of short-time cultivated CTCs shows elements with gemistocytic pattern and
moderate nuclear atypia. The black arrow shows a cluster of cells with eosinophilic cytoplasm. Scale bars: 100 μm. In d Tissue biopsy, H&E staining
of histologic glioblastoma specimen. Please note the necrosis, the atypical astrocytic cell proliferation, and the gemistocytic features. Scale bars:
100 μm. Case 2. In e pre-operative MRI of the head shows acystic expansion entrapping the temporal horn of the left lateral ventricle with controlateral
dislocation of the ventricular system. In f MRI, performed during the follow up after treatment shows left-sided cyst and dilated ventricle with reduction
of contrast-enhanced MRI of the primary lesion. In g H&E staining of cytological elements on slides obtained by short-time expansion of CTCs. Please
note large, round elements with abundant cytoplasm, indicated by four black arrows. Scale bars: 100 μm. In h H&E staining of excisional biopsy shows
Diffuse Large B-Cell Lymphoma. Scale bars: 100 μm
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ventricle with an extensive periventricular hypodensity
area and controlateral dislocation of the ventricular
system.
Preoperative imaging demonstrated that the primi-
tive lesion displayed a high density on CT scans.
Contrast-enhanced MRI showed a T1-hypointense and
T2-hyperintense lesion. The signals were significantly
enhanced by the contrast (Fig. 2e).
The patient was advised to undergo stereotactic biopsy
procedures. During the pre-operative phase, a blood
sample was collected for CTCs detection. The resulting
slides were analysed by the pathologist who suspected
a lymphoma for the morphology of neoplastic cells
highlighted by H&E staining (Fig. 2g). The patient under-
went CT scans with and without contrast for the upper
abdomen, the lower abdomen and the thorax. Scans con-
firmed that the lymphoma was exclusively localized in the
intracranial area. In this case, the CTCs were not charac-
terized for mesenchymal antigens as reported for the first
case. Given the cytological analysis and neuroimaging
data, diffuse large B-cell lymphoma diagnosis was directly
confirmed by immunostaining for CD20 on tissue biopsy
specimen. Therapy with high doses of corticosteroids re-
sulted in a nearly complete disappearance of the primary
lesion and improvement in the patient’s general state of
health. We made a stereotactic biopsy of the primary tem-
poral lesion and stereotactic placing of external ventricular
shunt by a ventricular catheter positioned into the left
temporal horn. The patient responded well in the post-
operative phase and recovered within 3 days of surgery
whilst continuing the anti-oedema therapy. During the
second post-operative day there was an appreciable im-
provement in clinical symptoms. The neurological deficits
completely disappeared after the therapy. Follow-up CT
scans showed adequate decompression of the temporal
horn and disappearance of the ventricular low-density
area. The midline shift disappeared as well.
In the following days the patient underwent a whole
body fluorodeoxyglucose (FDG)-positron emission tom-
ography (PET) that, despite its spatial and biological
limits of resolution, showed no areas of pathological
increase in glucose metabolism in the body regions
examined. FDG-PET brain did not recognize areas of
significant alteration in glucose metabolism in various
cortical, subcortical and subtentorial districts. These data
confirm that the lymphoma is primitive and exclusively
of the brain.
On histopathological examination of the surgical
specimen (Fig. 2h), the initial hypothesis of a brain
lymphoma was confirmed, revealing a CD20pos large B
cell lymphoma with high proliferation index (Ki67 Posi-
tivity) greater than 70 %. Subsequently, the patient was
referred to our medical oncology outpatient clinic where
he was followed carefully. The external ventricular shunt
was removed because of the high risk of infection.
Chemotherapy cycle was prescribed with the following
scheme: rituximab 375 mg/mq on day 1, methotrexate
3500 mg/mq on day 2, cytosine arabinoside 2 gr/mq doses
twice daily on day 2,3, thiotepa 30 mg/mq on day 4
(weight 78 kg, height 178 cm, body surface area 1,9 mq,
total dose rituximab 700 mg, methotrexate 6650 mg, cyto-
sine arabinoside15,2 g, thiotepa 60 mg). Treatment was
generally well tolerated by the patient and currently (fol-
low up after 8 months MRI in Fig. 2f) the patient’s general
condition are good.
Conclusions
In our limited experience, there are no obvious patho-
logical difference between excisional and liquid biopsy in
diagnostic evaluation of space-occupying brain lesions,
as confirmed in the cases presented here. In the exci-
sional biopsy, the tissue organization can address the
diagnostic procedure better than the cytological samples
obtained through the liquid biopsy. On the other hand,
as demonstrated in these cases, this condition is not
strictly needed to formulate a correct diagnosis. In the
first case, we were able to identify the mesenchymal
phenotype of circulating tumor cells, consisting in
Vimentin expression. This information implemented
with neuroimaging has strongly suggested the early diag-
nosis of high grade astrocytic tumor. This multidisciplin-
ary approach, in both cases, was able to highlight the
nature of the primary lesion. Moreover, in case 1, the
Vimentin-positivity of CTCs was also used in a personal-
ized monitoring of the patient, allowing an early detec-
tion of the disease recurrence.
Furthermore, many neurological disorders can mimic
clinically a tumor and there are diseases in which the neu-
roimaging is not sufficient to solve diagnostic problems.
The cases reported here show the possibility of
discriminating intracranial pathology through a simple
blood test. The possibility of performing non-invasive
biopsy procedures to obtain real time precious informa-
tion can be considered an improvement for an early
diagnosis of brain lesions.
In every phase of neoplastic pathology it is useful
to have a source of tumor cells which permits the
characterization of the same. In fact, during chemo-
therapy or radiotherapy, we apply selective pressure
that modifies the tumor cells identified prior to ad-
ministrating the antitumor therapies. The availability
of CTCs allows us to perform a personalized monitoring
of the disease progress via both tracking the number of
cells and cell characterization. Moreover, the cost-
effectiveness analysis of the management of these cases
suggest that using CTCs as non-invasive real–time biopsy,
the costs currently employed in analogue cases by Health
Service can break down of 70 %.
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The protocol proposed here guarantees, respect to
other current methods, that the cell isolated are neoplas-
tic and representative of the primary lesion. In this
study, we focalize on the CTCs phenotype but, this
protocol can be also used for genotyping, DNA/sRNA
analysis, and external vesicle production, with the advan-
tage to discriminate the cancer cells from contaminating
hematological cells. More cases must be studied to con-
firm these preliminary results.
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